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Peptides and proteins ﬁnd an ever-increasing number of applications in the biomedical and materials engineering
ﬁelds. The use of non-proteinogenic amino acids endowed with diverse physicochemical and structural features
opens the possibility to design proteins and peptides with novel properties and functions. Moreover, non-
proteinogenic residues are particularly useful to control the three-dimensional arrangement of peptidic chains,
which is a crucial issue for most applications. However, information regarding such amino acidssalso called
non-coded, non-canonical, or non-standardsis usually scattered among publications specialized in quite diverse
ﬁelds as well as in patents. Making all these data useful to the scientiﬁc community requires new tools and
a framework for their assembly and coherent organization. We have successfully compiled, organized, and
built a database (NCAD, Non-Coded Amino acids Database) containing information about the intrinsic
conformational preferences of non-proteinogenic residues determined by quantum mechanical calculations,
as well as bibliographic information about their synthesis, physical and spectroscopic characterization,
conformational propensities established experimentally, and applications. The architecture of the database is
presented in this work together with the ﬁrst family of non-coded residues included, namely, R-tetrasubstituted
R-amino acids. Furthermore, the NCAD usefulness is demonstrated through a test-case application example.
Introduction
The repertoire of amino acids currently available for applica-
tion in life and materials sciences is rapidly expanding. Besides
the 20 genetically coded R-amino acids contained in proteins,
more than 700 different amino acids have been found in Nature1
(most of them, also R-amino acids), and many others have been
synthesized by organic chemists.1a,2 These residues are joined
under the common name of non-proteinogenic or non-coded
amino acids (nc-aa). Although they are rigorously excluded from
ribosomally synthesized native peptides and proteins, several
naturally occurring peptides (produced non-ribosomally) have
been found to contain nc-aa.2i,3 Additionally, they are increas-
ingly used to improve the pharmacological proﬁle of natural
peptides endowed with biological activity4 (to confer resistance
against enzymatic degradation, enhance membrane permeability,
or increase selectivity and afﬁnity for a particular receptor). Nc-
aa have also led to the development of efﬁcient drugs of non-
peptidic nature.5 Moreover, recent advances in biotechnology
have paved the way for protein engineering with nc-aa.6 Thus,
proteins containing residues with ﬂuorescent,7 redox-active,8 or
photosensitive groups7c,9 or other side chains endowed with
speciﬁc chemical reactivity10 or spectroscopic properties11 may
serve as biosensors and spectroscopic or biophysical probes, as
well as to construct systems for drug delivery and diagnosis
through imaging useful in medicine.6-11 Nc-aa have also found
application in nanobiology to promote the self-assembly of
nanostructures.12 Other remarkable applications of nc-aa include
the development of bioinspired synthetic organic polymers that
emulate the shape and properties of natural peptides and
proteins.13
In spite of the great signiﬁcance and potential utility of nc-
aa in modern biology, biomaterials engineering, and medicine,
structural information is only available for a limited number of
them. Speciﬁcally, the intrinsic conformational preferences of
nc-aa, which are typically obtained by sampling the potential
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energy hypersurface of small peptide systems incorporating them
through sophisticated quantum mechanical calculations at the
ab initio or Density Functional Theory (DFT) levels in the
absence of external forces, have been reported for only several
tenths of these compounds. Knowledge of such intrinsic
conformational preferences is however essential to understand
the features that distinguish these nc-aa from the coded ones
and, therefore, for a complete and satisfactory exploitation of
their capabilities. Structural data yielded by crystallographic or
spectroscopic studies on peptide sequences incorporating nc-
aa are also available for an increasing number of cases.
Comparison of such experimental information with that derived
from high-level theoretical calculations helps establish the
inﬂuence of the external packing forces, the solvent effects, and
the chemical environment on the conformational propensities
of nc-aa.
In practice, the use of nc-aa with well-characterized confor-
mational properties is frequently limited because the relevant
information is highly dispersed. Indeed, the quantum mechanical
calculations describing the intrinsic conformational preferences
of these compounds are typically reported in physical chemistry
journals, while their synthesis appears in organic chemistry
publications. Crystallographic and spectroscopic studies of small
peptide sequences containing nc-aa are usually developed by
organic and peptide chemists and published in journals special-
ized in these ﬁelds. In contrast, many applications of nc-aa are
tested by researchers working on protein engineering, medicine,
or materials science. This highly dispersed information together
with the wide and diverse potential applications of nc-aa made
us realize that the design of a simple informatics tool integrating
the contributions supplied by the different research ﬁelds would
facilitate the use of these compounds in many practical
applications. To this aim, we have built a database of nc-aa
containing the fundamental conformational descriptors and
relevant bibliographic information about experimental studies
and already developed practical applications. This user-friendly
online facility is intended as an aid to the development of new
applications by combining the structural descriptors with
thermodynamics criteria for a proper selection of nc-aa compat-
ible with the user-deﬁned requirements.
In this work, we present NCAD (Non-Coded Amino acids
Database), a database conceived and created to identify the nc-
aa that are compatible with a given structural motif, which is
the key requirement for the application of these compounds in
life and materials sciences. The database integrates structural
and energetic descriptors of those nc-aa whose intrinsic con-
formational properties have been previously studied using ab
initio or DFT quantum mechanical calculations and reported in
the literature. The information about NCAD presented in the
following sections is organized as explained next. First, the most
relevant aspects of the database are described, such as structure,
contents, technical features, and relationships allowed among
the different descriptors. Next, R-tetrasubstituted R-amino acids,
being the ﬁrst family of nc-aa integrated into the database, are
presented. The conformational preferences of these compounds,
which have been the subject of extensive study by our research
groups, are examined and discussed using the overall informa-
tion captured in the database. Finally, the utility and applicability
of the database is illustrated with a simple example. Speciﬁcally,
conformationally restricted analogues of the neuropeptide Met-
enkephalin are designed through targeted replacements with nc-
aa, using the information incorporated in the database.
NCAD: Contents, Tools, and Technical Features
Figure 1 portrays the NCAD contents. The information
contained in the database for each nc-aa is the following:
(a) A complete description (dihedral angles, three-dimensional
structure, relative energy, etc.) of all the minimum energy
conformations found for each amino acid using ab initio or DFT
quantum mechanical calculations. It should be noted that such
theoretical studies are carried out on small peptide systems of
general formula RCO-Xaa-NHR′ (Xaa ) amino acid; R and R′
) Me or H). When several theoretical studies were available
in the literature for a particular amino acid, the information was
extracted from that using the highest level of calculation.
Conformational studies based on calculations less accurate than
ab initio or DFT methods, i.e., molecular mechanics based on
classical force ﬁelds, semiempirical procedures, etc., have not
been considered for NCAD. It is worth noting that only in a
few cases are the atomic coordinates of the minimum energy
conformations supplied by the authors as Supporting Information
of the original article. Accordingly, to incorporate such coor-
dinates into the database for all nc-aa, all minimum energy
conformations for which coordinates were not available have
been recalculated using the same theoretical level as in the
original study. Although this is an arduous and extremely time-
consuming task, we considered it essential for the usefulness
of the database. Throughout the theoretical works describing
the conformational propensities of nc-aa, different nomenclature
systems are used to term the energy minima located. We have
uniﬁed them so that only the nomenclature introduced by Perczel
et al.14 is used in NCAD to identify the backbone conformation
of the different minima characterized for each amino acid.
According to it, nine different conformations can be distin-
guished in the potential energy surface E ) E(φ,ψ) of R-amino
acids,14 namely, γD, δD, RD, εD, DL, εL, RL, δL, and γL. This
information is particularly useful to check the compatibility of
the minima energetically accessible to a particular nc-aa with
the secondary structure motifs typically found in peptides and
proteins (helices, sheets, turns, etc.).
(b) Bibliographic information related to experimental data,
when available. Selected references describing the synthesis and
characterization of each particular amino acid in its free form,
as a salt, or with the amino group adequately protected for use
in peptide synthesis are given. Also, references providing
experimental information about the conformational preferences
of the amino acid are included in NCAD. These concern mainly
Figure 1. Schematic graphic algorithm showing the structure of the
NCAD database.
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structural studies of peptides incorporating nc-aa using either
spectroscopic or crystallographic techniques. Furthermore, in
selected cases, atomic coordinates extracted from X-ray crystal
structures have also been included in the database. Such three-
dimensional structures allow a direct comparison with the
minimum energy conformations predicted by theoretical cal-
culations. Upon request and permission of the authors, we plan
to include in NCAD examples of crystal structures of peptide
sequences incorporating different nc-aa. This does not intend
to be comprehensive since we are aware that the crystal
structures of peptides and proteins containing nc-aa are already
stored in specialized databases, like the Cambridge Structural
Database15 (CSD) and the Protein Data Bank16 (PDB).
(c) Applications reported for each particular nc-aa divided
into two main categories, namely, those related to the biological
properties of the amino acid (or compounds incorporating it)
and applications in materials science. The most relevant
publications in each ﬁeld, either papers in scientiﬁc journals or
patents, are given.
As commented above, NCAD has been conceived to contain
all those nc-aa whose intrinsic conformational propensities have
been determined through ab initio or DFT quantum mechanical
calculations. Such amino acids may be chiral or not. In the
former case, two enantiomeric forms do exist for a given amino
acid. Obviously, the conformational preferences of only one
enantiomer have been calculated and are included in the database
since those of the enantiomeric species may be obtained by
simply changing the signs of the dihedral angles. The biblio-
graphic information concerning synthesis, spectroscopic char-
acterization, experimental structural properties, and applications
included in the database covers the two enantiomers as well as
the racemic form, when applicable.
Figure 2 shows the entity-relationship diagram17 (ERD) of
NCAD. This diagram summarizes the conceptual representation
of the information stored in the database, as well as their inter-
relational scheme. The entities are shown in squares; the
relationships are lines between boxes; and their multiplicities
are displayed using numbers or stars following ERD standards.
All the experimental and theoretical information in the database
has been extracted from relevant literature sources, and accord-
ingly, all data available in NCAD for a given amino acid are
connected with the bibliographic references. Labels (labelexp,
labelappli entities) allow the identiﬁcation of the applications
described for each amino acid as well as the experimental data.
The database also stores the atomic coordinates of the minimum
energy conformations (minimum) predicted by a particular
quantum mechanical method (theory), which have been ex-
tracted from the literature (bibliography), and its correspondence
with secondary structure motifs (conformation-secondary struc-
ture). Furthermore, internal coordinates, such as dihedral angles
(dihedrals) for both the backbone and the side chain, can be
easily obtained from the database for each minimum energy
conformation of a given amino acid.
NCAD can be easily used by non-experts in informatics since
the interface designed applies a simple windows system. This
system provides access to six folders. The ﬁrst one (Figure 3a)
is used to deﬁne the criteria (one or several, i.e., .AND. or .OR.)
applied to the search. These may be chosen among the
following: (i) the chemical nature of the side chain, i.e.,
aromatic, aliphatic, charged, or polar (non-charged); (ii) the
category, which corresponds to the structural feature distin-
guishing a particular family of nc-aa, e.g., R-tetrasubstituted
R-amino acids, dehydro R-amino acids, N-substituted R-amino
acids, ω-amino acids, etc.; (iii) the molecular formula of the
amino acid; (iv) the type of backbone conformation located
among the energy minima, according to the nomenclature
established by Perczel et al.,14 i.e., γD, δD, RD, εD, DL, εL, RL,
δL, and γL; (v) the (φ,ψ) backbone dihedral angles corresponding
Figure 2. Chen’s diagram showing the relationships among the entities
in NCAD.
Figure 3. Interface system used to interact with the NCAD database.
(a) Window used to perform the search. (b) Window showing details
about the theoretical study at the highest quantum mechanical level
reported in the literature for the nc-aa selected; the Rasmol 3D-view
of a selected minimum energy conformation and the report are also
displayed (both are generated through internal calls of the interface
upon the user’s request).
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to such energy minima, with both the values and the tolerance
being speciﬁed by the user; (vi) the name of the researcher who
performed the theoretical or experimental investigation (author);
(vii) the experimental studies reported in the literature relative
to synthesis and characterization or to conformational properties;
and (ix) the applications (in medicine or materials science)
described.
The amino acids fulﬁlling all the selected criteria are displayed
in a list (Figure 3a) (by default, when no criterion is speciﬁed,
all residues included in NCAD are listed), and a report with
the search criteria and results may be generated. The user can
select three different nomenclatures to indicate the amino acid
names: systematic, common, or abbreviated (usually resembling
the three-letter code used for proteinogenic amino acids), e.g.,
2-amino-2-methylpropanoic acid, R-aminoisobutyric acid, or
Aib, respectively. It should be noted that the common and
abbreviated names are not available for all residues.
Selection of an amino acid from this list allows access to all
the information stored in the database for this particular residue,
which is presented in the remaining ﬁve folders. The “general
info” folder provides the chemical description of the amino acid,
including a graphical scheme of its chemical structure and the
types of experimental studies and applications available. These
data together with the corresponding bibliographic references
stored in the database for the selected amino acid may be
exported to a report. The “conformations” folder (Figure 3b)
displays information extracted from the theoretical study
performed at the highest quantum mechanical level reported in
the literature. Speciﬁcally, it includes the bibliographic source,
the number of minima characterized, the list of dihedral angles
and energy of each minimum, the position of each minima
within the Ramachandran map, and the quantum mechanical
method used in the theoretical study. A report containing this
information may be generated. Furthermore, this folder allows
a graphical inspection of each minimum energy conformation
with the molecular visualization software Rasmol.18 This is made
possible by accessing the atomic coordinates stored in the
database through an internal call of the interface. The atomic
coordinates of each minimum energy conformation may be also
extracted. The next two folders provide bibliographic data about
experimental studies (synthesis and characterization, confor-
mational propensities) and reported applications in medicine and
materials science. Such bibliographic information is not intended
to be comprehensive but rather present some signiﬁcant publica-
tions in the ﬁeld. Thus, these folders supply essential information
reported for the amino acid considered, but a systematic
literature search is recommended if this amino acid is ﬁnally
selected by the user for practical applications. Finally, the last
folder allows access to the X-ray crystal structures of peptide
sequences containing the selected amino acid that are available
in the database. Three-dimensional visualization of these
structures is made through the Rasmol software.18
r-Tetrasubstituted r-Amino Acids
Because of our interest in R-tetrasubstituted R-amino acids
and their relevance in the design of peptides with well-deﬁned
conformational properties,19 this is the ﬁrst family of nc-aa
integrated into NCAD. Table 1 lists the 29 R-tetrasubstituted
R-amino acids whose intrinsic conformational propensities have
been determined to date using ab initio or DFT quantum
mechanical methods20-37 according to a literature search. This
list is expected to be dynamic and thus be updated when studies
on new compounds in this category are reported. Other families
of nc-aa will be integrated into NCAD in the near future.
R-Tetrasubstituted amino acids are characterized by an
R-carbon atom bearing four substituents (different from hydro-
gen) and hence are also called quaternary amino acids. They
are usually divided into two subtypes, depending on whether
the R carbon is involved in a cyclic structure or not. Notably,
the former has been studied much more frequently, the number
of entries in the database being 24 and 5, respectively. Regarding
chirality, 9 residues in Table 1 present two identical substituents
at the R carbon and are therefore achiral, namely, Aib, Ac3c,
Dpg, Dbg, Ac4c, Ac5c, Adt, Ac6c, and Toac. The remaining 20
amino acids present at least one chiral center. In the latter case,
only the low energy minima of one enantiomer (usually L) have
been considered for incorporation into NCAD, those of the other
enantiomer being easily deducible by simply changing the sign
of both (φ,ψ) angles. When two or more chiral centers are
present in the molecule, the stereochemistry is indicated through
the R/S instead of the L/D nomenclature (the S conﬁguration at
the R carbon usually corresponding to L).
Figure 4 presents Ramachandran maps corresponding to the
(φ,ψ) backbone dihedral angles of all the energy minima
reported for the 29 R-tetrasubstituted R-amino acids included
in the database.20-37 Those chiral in nature (Figure 4a) are
represented together with the minima calculated by ab initio
quantum mechanical methods for the N-acetyl-N′-methylamide
derivative of L-alanine38 (MeCO-Ala-NHMe), as a reference for
proteinogenic amino acids. The non-chiral R-tetrasubstituted
residues (Figure 4b) are compared with the glycine minima
(calculated ab initio on MeCO-Gly-NHMe38). The latter map
is centrosymmetric since two points (φ,ψ) and (-φ,-ψ) are
equivalent for achiral amino acids.
As can be seen, tetrasubstitution at the R carbon affects the
location of the minimum energy conformations typically found
for proteinogenic residues. Speciﬁcally, the γL conformation
(intramolecularly hydrogen bonded seven-membered ring, also
denoted C7 conformation), which was found38 at (φ,ψ) )
(-86,79) and (-86,72) for Ala and Gly, respectively, tends to
evolve toward lower absolute ψ values upon replacement of
the R-hydrogen atom by a substituent. The distortion of the ψ
dihedral angle shown by quaternary R-amino acids is maximal
for 1-aminocyclopropanecarboxylic acid (Ac3c, Table 1), which
presents a γL minimum at (φ,ψ) ) (-77,34),21 as a consequence
of the peculiar stereoelectronic properties of the three-membered
ring.39
The ψ backbone dihedral angle characterized for the R-helix
conformation also deviates to lower absolute values when the
R carbon is tetrasubstituted. Thus, the RL conformation of Ala
was located at (φ,ψ) ) (-61,-41)38 (as was for Gly38), whereas
that of its R-methylated counterpart, R-aminoisobutyric acid
(Aib, Table 1), is found at (-65,-31).20 A similar trend, or
even more pronounced, is observed for most amino acids in
Table 1, either chiral or not. Thus, for example, Ac5c, Ac6c,
and L-c3Dip exhibit RL minima with (φ,ψ) values (-73,-15),27
(-70,-20),31 and (-80,-20),22 respectively. This apparently
minor change brings about important consequences, and indeed,
Aib and other quaternary R-amino acids are known to stabilize
the 310-helix19 rather than the R-helix typically found for
proteinogenic amino acids. The slight difference in the backbone
dihedral angles translates into signiﬁcant variations in the
parameters associated to each helical structure, including the
hydrogen bonding pattern, which involves residues i and i+3
in the 310-helix and residues i and i+4 in the R-helix.40
Quaternary R-amino acids can therefore be used to design helical
structures exhibiting hydrogen-bonding schemes and geometries
different from those formed by standard amino acids.
7416 J. Phys. Chem. B, Vol. 114, No. 21, 2010 Revilla-Lo´pez et al.
Another effect of R-tetrasubstitution is the stabilization of
minimum energy conformations that are not usually detected
experimentally for coded amino acids because they are energeti-
cally unfavored. This feature is clearly observed when only the
minima found for quaternary amino acids within a relative
energy interval of 2.0 kcal/mol, i.e., those energetically acces-
sible, are considered and compared with Ala or Gly (see Figures
5a and 5b for chiral and achiral residues, respectively). Specif-
ically, the εD and εL regions of the (φ,ψ) map are visited
by some R-tetrasubstituted amino acids, like Aib20 and
(1S,2R)c3Phe,21 but not by Ala38 or Gly.38 Furthermore, the RL
conformation is energetically accessible to several of the nc-aa
considered, whereas the Ala38 RL minimum is unfavored by
nearly 4.0 kcal/mol with respect to the global minimum. The
same holds true for Gly.38 Moreover, minima in the RD region
are found under the threshold of 2.0 kcal/mol for several amino
acids in Table 1, among which are not only those of achiral
nature, and therefore presenting an identical propensity to
accommodate RL and RD conformations, but also some exhibit-
ing an L conﬁguration, like (1S,2S)c5Arg.30 Therefore, tetrasub-
stitution at the R carbon may result in the stabilization of
conformations typically accessed by D amino acids even if the
L chirality is maintained.
The features commented on above illustrate the great con-
formational impact that may derive from the presence of
R-tetrasubstituted amino acids in a peptide chain, which has
been demonstrated in numerous investigations.19,40 Nowadays,
the usefulness of this family of nc-aa in the control of peptide
conformation is beyond doubt, but the practical application to
the design of biologically relevant molecules or peptide-based
materials is only in its earliest stages. NCAD is intended to
mean a signiﬁcant contribution to its development.
In Silico Molecular Engineering for Targeted
Replacements in Met-Enkephalin Using NCAD: A Test
Case
We provide in this section a computational design study
aimed at constructing mutants of Met-Enkephalin using infor-
mation extracted from NCAD. This is not intended to provide
a deep and rigorous investigation of the resulting peptides but
to illustrate the potential utility of the database in applications
involving peptide and protein engineering through a test case.
TABLE 1: r-Tetrasubstituted r-Amino Acids Stored in NCADa
a The systematic name (and the common and abbreviated names,b when available), the chemical structure, and the reference reporting the
quantum mechanical study are given for each amino acid. b In the abbreviated name, the conﬁguration is deﬁned by the L/D nomenclature when
only the R carbon is chiral (L usually corresponding to S). When two or more chiral centers are present, the R/S stereochemical descriptors are
used instead.
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The Met-enkephalin neurotransmitter is a pentapeptide (Tyr-
Gly-Gly-Phe-Met) that interacts with opioid receptors.41 Opioid
systems play a signiﬁcant role in pain medication and opiate
dependence, regulate dopamine release, and are thought to be
important for drug-induced reward. Interestingly, no unique
native structure has been found for Met-enkephalin, whose
conformational ﬂexibility has been examined using a wide vari-
ety of experimental techniques (e.g., X-ray crystallography,
NMR, circular dichroism, and infrared, ultraviolet, and ﬂuo-
rescence spectroscopies).42 Accordingly, this short peptide is
able to adopt different conformations depending on the biologi-
cal context, which explains its ability to interact with opioid
receptors of the μ, κ, and δ types.41 The multiple conformational
states accessible to Met-enkephalin are therefore at the basis of
its poor selectivity of action. A number of theoretical studies
using both conventional and advanced simulation methods based
on molecular dynamics (MD) and Monte Carlo (MC) algorithms
have been devoted to explore the energy landscape of Met-
enkephalin and have shown its ill-deﬁned conformational
state.43-45
We have examined the information stored in NCAD to
propose targeted replacements able to stabilize one of the
conformations experimentally detected for Met-enkephalin.
Speciﬁcally, we considered the conformation identiﬁed by NMR
for Met-enkephalin in fast-tumbling bicelles.46 The atomic
coordinates of this conformation were extracted from the Protein
Data Bank16 (PDB code: 1PLW).
The peptide was placed in the center of a cubic simulation
box (a ) 44.6 Å) ﬁlled with 2916 explicit water molecules,
which were represented using the TIP3 model.47 The N- and
C-termini were described using the positively charged am-
monium and the negatively charged carboxylate groups, re-
spectively. All the MD simulations were performed using the
NAMD computer program.48 To equilibrate the density of the
simulation box, different consecutive rounds of short MD runs
were performed. Thus, 0.5 ns of NVT-MD at 350 K was used
to homogeneously distribute the solvent in the box. Next, 0.5
ns of NVT-MD at 298 K (thermal equilibration) and 0.5 ns of
NPT-MD at 298 K (density relaxation) were run. After this,
the peptide conformation was equilibrated by running a 3 ns
trajectory of NVT-MD at 298 K. The last snapshot of this
trajectory was used to determine the (φ,ψ) dihedral angles of
the three central residues of Met-enkephalin (Gly-Gly-Phe),
which deﬁne the most ﬂexible region of the peptide. The (φ,ψ)
values thus obtained were (83,77) for Gly2, (61,-81) for Gly3,
and (-66,-38) for Phe4, which correspond to the RD, γD, and
RL conformations, respectively, according to Perczel’s nomen-
clature.14
These structural parameters have been used to design targeted
substitutions in Met-enkephalin aimed at reducing the ﬂexibility
of the peptide backbone so that the particular conformation
selected is stabilized. This molecular design pursues the
validation of the performance and usefulness of the NCAD
database. The following criteria were considered in the design:
(i) the side chain functionality of the nc-aa selected should be
similar to that of the natural residue to be replaced, which is
essential to preserve the biological functions of the peptide and
(ii) the intrinsic conformational properties of the selected nc-aa
must be consistent with the conformation adopted by the targeted
residue in the parent peptide. On the basis of these selection
criteria and the structural parameters provided by MD for the
Gly-Gly-Phe peptide fragment, three different mutations were
proposed using the information in NCAD:
(a) Replacement of Gly2 or Gly3 by R-aminoisobutyric acid
(Aib, see Table 1). This amino acid bears two methyl groups at
the R position (instead of the two R-hydrogen atoms in Gly)
and presents low-energy minima20 located at the RL and γL
regions of the Ramachandran map, with (φ,ψ) angles (-65,-31)
and (-76,58) and relative energies 1.7 and 0.0 kcal/mol,
respectively, at the MP2/6-31G(d)//HF/6-31G(d) level. Given
the non-chiral nature of Aib, these minimum energy conforma-
tions are equivalent to the enantiomeric RD and γD, characterized
by (φ,ψ) dihedrals (65,31) and (76,-58), respectively. The latter
values ﬁt very well with those provided by MD for the Gly2
Figure 4. Ramachandran maps showing all the minimum energy
conformations predicted by quantum mechanical calculations for the
R-tetrasubstituted R-amino acids included in NCAD (see Table 1): (a)
chiral residues (black squares) compared with Ala (gray squares); (b)
achiral residues (black squares) compared with Gly (gray squares).
Figure 5. As in Figure 4, but only minimum energy conformations
with a relative energy below 2.0 kcal/mol are considered.
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[(83,77)] and Gly3 [(61,-81)] residues of Met-enkephalin. The
mutants resulting from these substitutions are denoted G2 and
G3.
(b) Replacement of Phe4 by (2R,3R)-1-amino-2,3-diphenyl-
cyclopropanecarboxylic acid, known in the abbreviated form
as (2R,3R)c3diPhe. This cyclic R-tetrasubstituted residue contains
a cyclopropane ring bearing two vicinal phenyl substituents in
a trans relative disposition [see the (2S,3S) enantiomer in Table
1]. It retains the side chain of Phe and shows an energy
minimum of the RL type characterized by (φ,ψ) values
(-67,-27),23 which closely resemble those obtained for Phe4
in Met-enkephalin in the MD trajectory described above,
(-66,-38). Moreover, (2R,3R)c3diPhe has been shown experi-
mentally to exhibit a high propensity to adopt RL conformations
due to the interaction between the two rigidly held aromatic
groups and the peptide backbone.49 The mutant resulting from
the replacement of Phe4 by (2R,3R)c3diPhe in Met-enkephalin
is denoted F4.
MD trajectories of 6 ns were performed for the wild-type
peptide and the three mutants designed. The starting geometries
for the mutants were constructed using the coordinates stored
in the database for the minimum energy conformation selected
for each nc-aa. The protocols applied for thermal equilibration
and density relaxation were identical to those described above.
All the force-ﬁeld parameters for the MD simulations were
extracted from the AMBER libraries,50 with the exception of
the electrostatic charges for the nc-aa, which were taken from
the papers quoted in the database.
Figure 6 shows the accumulated Ramachandran plots obtained
through 6 ns of simulation corresponding to the Gly2, Gly3,
and Phe4 residues for the wild-type peptide. As can be seen,
the two Gly residues sample all the accessible regions of the
(φ,ψ) space, which is consistent with the large conformational
ﬂexibility observed for Met-enkephalin in aqueous solution by
both experimental42a,b,d-f and theoretical techniques.43-45 The
Phe4 residue also exhibits a great ﬂexibility, although it only
explores conformations in the left-half part of the map, as
expected from its L conﬁguration (in comparison, for the non-
chiral Gly residue, the left and right parts of the map are
energetically equivalent). Therefore, all three residues are
actually found to adopt (φ,ψ) values in all the regions that
are energetically accessible to them. In other words, no
selectivity is detected toward a particular structure among those
allowed to L (in the case of Phe) or achiral (in the case of Gly)
coded residues. It is worth noting that the sampling of the
conformational space shown in Figure 6 is in excellent agree-
ment with that obtained for the same peptide using replica
exchange MD.45
Figure 7 shows the (φ,ψ) distributions obtained for the nc-
aa included in mutants G2, G3, and F4 of Met-enkephalin. Table
2 displays the population of the different backbone conforma-
tions, which is expressed in terms of number of visits to a certain
region of the Ramachandran map during the MD trajectories.
These data provide evidence for the great conformational
selectivity induced by the R-tetrasubstituted amino acids used.
In particular, for the G2 mutant, the Aib residue (Gly2 substitute)
falls exclusively in the RD region. Accordingly, the substitution
designed using NCAD successfully restricts the conformational
ﬂexibility of the Gly2 residue and, moreover, preserves the
selected arrangement. Thus, the replacement of Gly2 by Aib
results in the stabilization of the conformation adopted by the
coded residue in the starting geometry.
Replacement of Gly3 by Aib also has a conformational
conﬁnement effect although less intense. Indeed, only the RD,
γD, and εD structures are adopted by the Aib residue in the G3
mutant (Figure 7), their respective populations being 29.5%,
66.1%, and 4.4% (Table 2). In contrast, Gly3 in the unmodiﬁed
peptide was found to visit all nine regions used by Perczel et
al.14 to describe the conformational space. We also note that
the two regions most populated by Gly3 in the wild-type system,
namely, RD and γD, are kept by Aib in the G3 mutant. Thus,
although the Gly-Aib exchange proved less restrictive in G3
than in G2, the results obtained for the G3 mutant illustrate
again that properly selected nc-aa can be successfully used to
reduce the conformational freedom of biological (macro)mol-
ecules through the stabilization of selected secondary structure
motifs.
To further evidence the magnitude of the conformational
restrictions introduced by the nc-aa in this study, Table 3
displays the ratio between the populations of the conformations
found for the quaternary R-amino acids and those of the
corresponding coded residues in the wild-type peptide. For
instance, mutant G3 increases the population obtained for the
γD conformation of Gly3 in Met-enkephalin by a factor of 2.2.
In the F4 mutant, the restricted geometry of (2R,3R)c3diPhe
affects mainly the φ angle, which remains ﬁxed in the neighbor-
hood of -60° during the whole MD trajectory (Figure 7). In
Figure 6. Backbone (φ,ψ) dihedral angle distributions obtained for
the Gly2, Gly3, and Phe4 residues in wild-type Met-enkephalin.
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comparison, the Phe4 residue in Met-enkephalin was found to
cover all the possible negative values of φ: -180° < φ < -50°
(Figure 6). As a result, the RL conformation, which corresponds
to that adopted by Phe4 in the original arrangement selected,
signiﬁcantly increases its population from the wild-type peptide
(34.4%) to the F4 mutant (82.2%) and becomes the most visited
structure during the simulation of the latter peptide. The
selectivity ratio for the F4 mutant is 4.5 and 2.4 for the γL and
RL regions, respectively (Table 3). Accordingly, the nc-aa used
as a Phe4 substitute also stabilizes the desired conformation
and further proves the utility and potential applicability of the
new database.
Conclusions
NACD (Non-Coded Amino acids Database) is an easy-
to-use research tool that integrates the intrinsic conforma-
tional preferences of non-coded amino acids to facilitate their
use in the design of peptide- or protein-based compounds
useful in different ﬁelds of life and materials sciences. Our
aim is to provide the outcome of structural studies of nc-aa,
including their properties and chemical characteristics,
obtained by scientists in the organic and physical chemistry
disciplines to those focusing on biological, bioengineering,
and medicinal applications, bringing the ﬁelds together. The
information provided in NCAD, which is not available in
other databases, is also expected to be a useful resource for
protein designers, modelers, and experts in bioinformatics.
The present paper presents the structure and informatics
architecture of the database, the interface that connects the
database with the users, the description of the ﬁrst family of
nc-aa integrated into the database (R-tetrasubstituted R-amino
acids), and a test case showing the applicability of the
database. Researchers can now easily select the most ap-
propriate residue from a collection of nc-aa with well-
established conformational properties and introduce it in a
peptide sequence or any other (macro)molecule. Additional
families of non-proteinogenic amino acids will be included
in NCAD in due course.
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